C. Lerchenmueller

430 total citations
7 papers, 79 citations indexed

About

C. Lerchenmueller is a scholar working on Oncology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C. Lerchenmueller has authored 7 papers receiving a total of 79 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 2 papers in Genetics and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C. Lerchenmueller's work include Colorectal Cancer Treatments and Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). C. Lerchenmueller is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (2 papers). C. Lerchenmueller collaborates with scholars based in Germany, Austria and Estonia. C. Lerchenmueller's co-authors include Thomas Decker, Tobias Heintges, Ursula Vehling‐Kaiser, Markus Moehler, Sebastian Stintzing, Thomas Kirchner, Ludwig Fischer von Weikersthal, Andreas Koehler, Dominik Paul Modest and Anja Welt and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

C. Lerchenmueller

6 papers receiving 79 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Lerchenmueller Germany 4 63 33 21 17 14 7 79
Heinz‐Gert Hoeffkes Germany 5 73 1.2× 41 1.2× 19 0.9× 15 0.9× 8 0.6× 13 82
Brad Somer United States 4 49 0.8× 38 1.2× 18 0.9× 12 0.7× 18 1.3× 4 99
Mariaelena Casagrande Italy 8 91 1.4× 45 1.4× 19 0.9× 22 1.3× 15 1.1× 21 123
Hongqian Wu United States 4 93 1.5× 28 0.8× 6 0.3× 16 0.9× 7 0.5× 6 121
Terri Goldberg United States 6 31 0.5× 30 0.9× 59 2.8× 32 1.9× 12 0.9× 11 98
Edward Y. Zhu United States 5 28 0.4× 26 0.8× 9 0.4× 12 0.7× 24 1.7× 13 73
Sabela Recalde Spain 5 41 0.7× 22 0.7× 10 0.5× 5 0.3× 12 0.9× 14 58
Helmut Lambertz Germany 4 81 1.3× 28 0.8× 21 1.0× 8 0.5× 8 0.6× 4 99
Baek‐Yeol Ryoo South Korea 4 64 1.0× 20 0.6× 23 1.1× 19 1.1× 8 0.6× 9 84
Yiu-Keung Lau United States 4 29 0.5× 20 0.6× 4 0.2× 5 0.3× 9 0.6× 10 53

Countries citing papers authored by C. Lerchenmueller

Since Specialization
Citations

This map shows the geographic impact of C. Lerchenmueller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Lerchenmueller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Lerchenmueller more than expected).

Fields of papers citing papers by C. Lerchenmueller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Lerchenmueller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Lerchenmueller. The network helps show where C. Lerchenmueller may publish in the future.

Co-authorship network of co-authors of C. Lerchenmueller

This figure shows the co-authorship network connecting the top 25 collaborators of C. Lerchenmueller. A scholar is included among the top collaborators of C. Lerchenmueller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Lerchenmueller. C. Lerchenmueller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Heß, Georg, Ulrich Keller, Paul La Rosée, et al.. (2020). Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. HemaSphere. 4(3). e398–e398. 9 indexed citations
2.
3.
4.
5.
Stintzing, Sebastian, Dominik Paul Modest, Ludwig Fischer von Weikersthal, et al.. (2014). Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in Fire-3 (Aio Krk-0306) in the Final Ras Evaluable Population. Annals of Oncology. 25. v1–v1. 47 indexed citations
6.
Dall, Peter, Friederike Siedentopf, Gerhard Klausmann, et al.. (2010). Abstract P5-12-01: Elderly Patients in a Prospective Observation Study on Trastuzumab (Herceptin®) in the Adjuvant Treatment of Breast Cancer. Cancer Research. 70(24_Supplement). P5–12. 1 indexed citations
7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heinz‐Gert Hoeffkes Breakdown of academic impact, for papers by Brad Somer Breakdown of academic impact, for papers by Mariaelena Casagrande Breakdown of academic impact, for papers by Hongqian Wu Breakdown of academic impact, for papers by Terri Goldberg Breakdown of academic impact, for papers by Edward Y. Zhu Breakdown of academic impact, for papers by Sabela Recalde Breakdown of academic impact, for papers by Helmut Lambertz Breakdown of academic impact, for papers by Baek‐Yeol Ryoo Breakdown of academic impact, for papers by Yiu-Keung Lau
Rankless by CCL
2026